The U.S. Food and Drug Administration (FDA) announced March 20 the approval of Zulresso (brexanolone) injection for intravenous (IV) use for the treatment of postpartum depression (PPD) in adult women. This is the first drug approved by the FDA specifically for PPD, a press release stated.
No takes yet. Share an insight, caveat, or question.
Valerie A. Canady (2019) studied this question.
Synapse has enriched 5 related papers. Consider them for comparative context: